IMUX Earnings Date: Nov 12, 2026 (Estimated) — Immunic, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IMUX's next earnings date?
Immunic, Inc. (IMUX) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.93.
How did IMUX do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Immunic, Inc. posted EPS of -$0.80 versus the -$1.16 estimate, a beat of 32.2%. Revenue was $0. The stock's 1-day post-earnings move was +9.8%.
How much does IMUX stock move after earnings?
IMUX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -1.16 | -0.80 | +32.20% | $0 | ✅ Beat | +9.79% | +13.69% | -13.55% |
| 2026-05-13 | Q1 2026 | -0.91 | -1.08 | -18.68% | $0 | ❌ Miss | +8.82% | -2.52% | +9.83% |
| 2026-02-26 | Q4 2025 | -0.11 | -0.07 | +36.36% | $0 | ✅ Beat | +4.10% | +28.51% | +38.40% |
| 2025-11-13 | Q3 2025 | -0.18 | -0.13 | +27.78% | $0 | ✅ Beat | -6.24% | -6.13% | -18.21% |
| 2024-11-07 | Q3 2024 | -0.22 | -0.24 | -9.09% | $0 | ❌ Miss | +0.00% | -0.85% | +8.47% |
| 2024-08-08 | Q2 2024 | -0.23 | -0.21 | +8.70% | $0 | ✅ Beat | +14.53% | +11.11% | +14.53% |
| 2024-05-08 | Q1 2024 | -0.26 | -0.30 | -15.38% | $0 | ❌ Miss | -7.97% | -7.25% | -10.14% |
| 2024-02-22 | Q4 2023 | -0.51 | -0.48 | +5.88% | $0 | ✅ Beat | -4.69% | +9.38% | +4.69% |
Showing last 8 quarters.